Skip to content

News
Exclusives
- Education
- Insights
- Interviews
- Media
- Reports
- Podcasts
Newsletter

News
Exclusives
- Education
- Insights
- Interviews
- Media
- Reports
- Podcasts
Newsletter

About Us
Contact us

About Us
Contact us

Search

News
Exclusives
- Education
- Insights
- Interviews
- Media
- Reports
- Podcasts
Newsletter

News
Exclusives
- Education
- Insights
- Interviews
- Media
- Reports
- Podcasts
Newsletter

About Us
Contact us

About Us
Contact us

Subscribe

Phase IIa

AI
Business
Capital Markets
Education
Exclusives
Insights
Interviews
Media
National
News
Press release
Product Release
Reports
Research
Robotics
Slider
Uncategorized

Insilico Medicine Reports Positive Phase IIa Results For a First-in-Class Drug Treatment For Idiopathic Pulmonary Fibrosis Designed by Generative AI

September 26, 2024

Insilico Medicine Reports Positive Phase IIa Results For a First-in-Class Drug Treatment For Idiopathic Pulmonary Fibrosis Designed by Generative AI

September 26, 2024

The AI Insider is the leading provider of media and market intelligence on the AI industry.

Featured News

Harvey Eyes $250M Funding at $5B Valuation as Legal AI Demand Surges

May 16, 2025

First Omnichannel Agentic AI Debuts as Forethought Secures $25M to Revolutionize Customer Engagement

May 16, 2025

Kovr.ai Emerges From Stealth With $3.6M to Reinvent Cyber Compliance Automation for Organizations in Highly Regulated Industries

May 16, 2025

Navigate

News
Exclusives
Newsletter

Contact Us

Email Us
Privacy Policy

PROJECTS

Resonance
The Quantum Insider
Digital Twin Insider
Space Insider
Climate Insider

2025 © Copyright Resonance Holdings Inc. All Rights Reserved

Cookies

We use cookies to improve your experience on our site. By continuing to browse our site, you consent to our use of cookies. For more details, you can manage your preferences under "Settings". Read our cookie policy

Settings Accept all

Cookies

Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy

Necessary
These cookies are not optional. They are needed for the website to function.
Statistics
In order for us to improve the website's functionality and structure, based on how the website is used.
Experience
In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
Marketing
By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.

Save Accept all

Gated Content

Subscribe today for the latest news about the AI landscape